SettingObesity surgery has been proposed as a treatment option for diabetic patients with body mass index (BMI)<35 kg/m2, but the efficacy of metabolic surgery has not been conclusively determined. ObjectivesTo evaluate the long-term metabolic outcome of non–morbidly obese (NMO) patients with type 2 diabetes (T2D) after biliopancreatic diversion (BPD). Material and methodsTwo groups of T2D patients with different degree of obesity (NMO, 17 cases, BMI 25–35 kg/m2; and morbidly obese [MO], 13 cases, BMI>35 kg/m2) were studied before and at 1 and 5 years after BPD in a university hospital setting. Insulin secretion was assessed by acute insulin response (AIR) to intravenous glucose and by insulinogenic index (IGI). ResultsIn all MO patients, T2D was remitted or controlled (1 case) at 1 year and results were maintained at 5 years; AIR (μU/mL) and IGI (μU/mg) improved (P<.001) at 1 year (from .1±3.1 to 18.52±21.9, and from 6.0±8.5 to 9.1±22.8, respectively) with a further increase (to 24.8±25.5 and to 14.3±13.8, respectively) at 5 years. Within the NMO group, T2D was remitted in 1/17 and controlled in 14/17 patients at 1 year, and in 2/17 and in 4/17 patients at 5 years, respectively; AIR (μU/mL) and IGI (μU/mg) remained unchanged throughout the postoperative period (from .31±9.26 to 1.5±2.8 at 1 yr and to .4±3.29 at 5 yr for AIR, and from 2.2±4.9 to 1.3±9.0 at 1 yr and to 2.3±3.3 at 5 yr for IGI). ConclusionsAfter BPD, restoration of β-cell secretion/production plays a pivotal role in determining postoperative T2D remission.
Read full abstract